Cargando…

Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales: Albshesh, Ahmad, Taylor, Joshua, Savarino, Edoardo V., Truyens, Marie, Armuzzi, Alessandro, Ribaldone, Davide G., Shitrit, Ariella Bar-Gil, Fibelman, Morine, Molander, Pauliina, Liefferinckx, Claire, Nancey, Stephane, Korani, Mohamed, Rutka, Mariann, Barreiro-de Acosta, Manuel, Domislovic, Viktor, Suris, Gerard, Eriksson, Carl, Alves, Catarina, Mpitouli, Afroditi, di Jiang, Caroline, Tepeš, Katja, Coletta, Marina, Foteinogiannopoulou, Kalliopi, Gisbert, Javier P., Amir-Barak, Hadar, Attauabi, Mohamed, Seidelin, Jakob, Afif, Waqqas, Marinelli, Carla, Lobaton, Triana, Pugliese, Daniela, Maharshak, Nitsan, Cremer, Anneline, Limdi, Jimmy K., Molnár, Tamás, Otero-Alvarin, Borja, Krznaric, Zeljko, Magro, Fernando, Karmiris, Konstantinos, Raine, Tim, Drobne, David, Koutroubakis, Ioannis, Chaparro, Maria, Yanai, Henit, Burisch, Johan, Kopylov, Uri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268494/
https://www.ncbi.nlm.nih.gov/pubmed/34209880
http://dx.doi.org/10.3390/jcm10132914
_version_ 1783720370883264512
author Albshesh, Ahmad
Taylor, Joshua
Savarino, Edoardo V.
Truyens, Marie
Armuzzi, Alessandro
Ribaldone, Davide G.
Shitrit, Ariella Bar-Gil
Fibelman, Morine
Molander, Pauliina
Liefferinckx, Claire
Nancey, Stephane
Korani, Mohamed
Rutka, Mariann
Barreiro-de Acosta, Manuel
Domislovic, Viktor
Suris, Gerard
Eriksson, Carl
Alves, Catarina
Mpitouli, Afroditi
di Jiang, Caroline
Tepeš, Katja
Coletta, Marina
Foteinogiannopoulou, Kalliopi
Gisbert, Javier P.
Amir-Barak, Hadar
Attauabi, Mohamed
Seidelin, Jakob
Afif, Waqqas
Marinelli, Carla
Lobaton, Triana
Pugliese, Daniela
Maharshak, Nitsan
Cremer, Anneline
Limdi, Jimmy K.
Molnár, Tamás
Otero-Alvarin, Borja
Krznaric, Zeljko
Magro, Fernando
Karmiris, Konstantinos
Raine, Tim
Drobne, David
Koutroubakis, Ioannis
Chaparro, Maria
Yanai, Henit
Burisch, Johan
Kopylov, Uri
author_facet Albshesh, Ahmad
Taylor, Joshua
Savarino, Edoardo V.
Truyens, Marie
Armuzzi, Alessandro
Ribaldone, Davide G.
Shitrit, Ariella Bar-Gil
Fibelman, Morine
Molander, Pauliina
Liefferinckx, Claire
Nancey, Stephane
Korani, Mohamed
Rutka, Mariann
Barreiro-de Acosta, Manuel
Domislovic, Viktor
Suris, Gerard
Eriksson, Carl
Alves, Catarina
Mpitouli, Afroditi
di Jiang, Caroline
Tepeš, Katja
Coletta, Marina
Foteinogiannopoulou, Kalliopi
Gisbert, Javier P.
Amir-Barak, Hadar
Attauabi, Mohamed
Seidelin, Jakob
Afif, Waqqas
Marinelli, Carla
Lobaton, Triana
Pugliese, Daniela
Maharshak, Nitsan
Cremer, Anneline
Limdi, Jimmy K.
Molnár, Tamás
Otero-Alvarin, Borja
Krznaric, Zeljko
Magro, Fernando
Karmiris, Konstantinos
Raine, Tim
Drobne, David
Koutroubakis, Ioannis
Chaparro, Maria
Yanai, Henit
Burisch, Johan
Kopylov, Uri
author_sort Albshesh, Ahmad
collection PubMed
description Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
format Online
Article
Text
id pubmed-8268494
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82684942021-07-10 Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study Albshesh, Ahmad Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro-de Acosta, Manuel Domislovic, Viktor Suris, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobaton, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero-Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri J Clin Med Article Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent. MDPI 2021-06-29 /pmc/articles/PMC8268494/ /pubmed/34209880 http://dx.doi.org/10.3390/jcm10132914 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Albshesh, Ahmad
Taylor, Joshua
Savarino, Edoardo V.
Truyens, Marie
Armuzzi, Alessandro
Ribaldone, Davide G.
Shitrit, Ariella Bar-Gil
Fibelman, Morine
Molander, Pauliina
Liefferinckx, Claire
Nancey, Stephane
Korani, Mohamed
Rutka, Mariann
Barreiro-de Acosta, Manuel
Domislovic, Viktor
Suris, Gerard
Eriksson, Carl
Alves, Catarina
Mpitouli, Afroditi
di Jiang, Caroline
Tepeš, Katja
Coletta, Marina
Foteinogiannopoulou, Kalliopi
Gisbert, Javier P.
Amir-Barak, Hadar
Attauabi, Mohamed
Seidelin, Jakob
Afif, Waqqas
Marinelli, Carla
Lobaton, Triana
Pugliese, Daniela
Maharshak, Nitsan
Cremer, Anneline
Limdi, Jimmy K.
Molnár, Tamás
Otero-Alvarin, Borja
Krznaric, Zeljko
Magro, Fernando
Karmiris, Konstantinos
Raine, Tim
Drobne, David
Koutroubakis, Ioannis
Chaparro, Maria
Yanai, Henit
Burisch, Johan
Kopylov, Uri
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_full Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_fullStr Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_full_unstemmed Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_short Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_sort effectiveness of third-class biologic treatment in crohn’s disease: a multi-center retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268494/
https://www.ncbi.nlm.nih.gov/pubmed/34209880
http://dx.doi.org/10.3390/jcm10132914
work_keys_str_mv AT albsheshahmad effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT taylorjoshua effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT savarinoedoardov effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT truyensmarie effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT armuzzialessandro effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT ribaldonedavideg effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT shitritariellabargil effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT fibelmanmorine effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT molanderpauliina effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT liefferinckxclaire effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT nanceystephane effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT koranimohamed effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT rutkamariann effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT barreirodeacostamanuel effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT domislovicviktor effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT surisgerard effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT erikssoncarl effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT alvescatarina effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT mpitouliafroditi effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT dijiangcaroline effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT tepeskatja effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT colettamarina effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT foteinogiannopouloukalliopi effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT gisbertjavierp effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT amirbarakhadar effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT attauabimohamed effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT seidelinjakob effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT afifwaqqas effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT marinellicarla effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT lobatontriana effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT pugliesedaniela effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT maharshaknitsan effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT cremeranneline effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT limdijimmyk effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT molnartamas effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT oteroalvarinborja effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT krznariczeljko effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT magrofernando effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT karmiriskonstantinos effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT rainetim effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT drobnedavid effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT koutroubakisioannis effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT chaparromaria effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT yanaihenit effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT burischjohan effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy
AT kopylovuri effectivenessofthirdclassbiologictreatmentincrohnsdiseaseamulticenterretrospectivecohortstudy